Is Cannabis Legal in Switzerland?

Medical Cannabis in Switzerland

Switzerland's medical cannabis framework underwent a fundamental shift in August 2022. Prior to that date, patients requiring cannabis-based medicines faced a bureaucratic hurdle: they needed an exceptional authorisation from the FOPH for each prescription. The 2021 revision of the Federal Act on Narcotics removed this requirement. From August 2022, any licensed physician can prescribe cannabis-based medicines, and patients can collect prescriptions from pharmacies without special intervention.

Swissmedic, Switzerland's medicines and medical devices regulatory authority, oversees the authorisation of pharmaceutical-grade cannabis products. Several imported and domestically produced products are available, covering conditions including chronic pain, multiple sclerosis-related spasticity, chemotherapy-induced nausea, and refractory epilepsy.

Switzerland's relatively liberal prescribing environment has attracted attention from European cannabis companies seeking favourable regulatory conditions. The country's non-EU status means it operates outside EMA frameworks, giving Swissmedic latitude to develop its own approval pathways. The private healthcare market — significant in Swiss society — also creates favourable conditions for patient-funded access where reimbursement is pending.

Decriminalisation and Possession Rules

Switzerland decriminalised possession of small quantities of cannabis for personal use in 2013, ahead of much of continental Europe. Adults found with up to 10g of cannabis are subject to a CHF 100 administrative fine — equivalent to a minor traffic penalty — and face no criminal record, court appearance, or lasting legal consequence. The threshold applies per incident; repeated infractions do not automatically escalate to criminal charges, though patterns may be considered by authorities.

Possession of quantities above 10g, or any activity construed as supply or trafficking, remains a criminal offence under the BetmG. The Swiss criminal code does not operate a separate cannabis-specific supply statute: supply is treated as a narcotics offence with penalties scaling to the quantity and nature of the activity. Cultivation for personal use occupies a grey area and is generally treated as possession for practical enforcement purposes, though the law does not formally sanction it.

The Adult-Use Pilot Programmes

Switzerland's most significant contribution to European cannabis policy is its structured approach to evidence-based adult-use trials. The 2021 revision of the BetmG inserted Article 8a, explicitly permitting cantonal and municipal authorities to run time-limited, science-based adult-use trials subject to FOPH approval. The provision is deliberately narrow: trials must have a scientific objective, must not involve commercial advertising, must be limited to registered adult participants, and must produce evaluable data.

Basel

Basel-Stadt was the first Swiss city to receive FOPH approval and launched its trial in early 2023. Participants register via the cantonal health authority and are allocated to one of several licensed dispensaries operating within the trial framework. The Basel trial covers a range of cannabis products including dried flower and extracts, at varying THC potencies. Participants complete surveys and provide biological samples for scientific analysis of consumption patterns, health outcomes, and substitution effects.

Bern and Zurich

Bern launched its pilot in mid-2023, with a focus on social consumption models alongside home consumption. Zurich, Switzerland's largest city, followed with a more expansive trial covering multiple dispensary locations and a larger participant cohort. The Zurich trial has attracted particular attention given the city's scale and the diversity of its participant pool, which includes both established cannabis users and individuals switching from the illicit market.

Geneva

Geneva's trial, approved in late 2023, operates across several pharmacies and specialist outlets. Geneva's trial is notable for its focus on harm reduction and its proximity to France, which creates cross-border policy dynamics that regulators on both sides are monitoring closely.

Business and Licensing

Switzerland presents a distinctive opportunity within the European cannabis landscape. Its non-EU status allows regulatory independence; its affluent population and well-funded healthcare system create favourable medical market conditions; and its liberal CBD framework — products with ≤1% THC are legal to retail — has established a mature hemp and CBD industry that provides infrastructure and expertise.

For operators seeking to cultivate or manufacture pharmaceutical-grade cannabis, Swissmedic licensing requires compliance with Swiss Good Manufacturing Practice (GMP) standards, which align broadly with EU-GMP. Switzerland's bilateral agreements with the EU cover some pharmaceutical regulatory areas, though cannabis is not subject to mutual recognition arrangements given its controlled substance status.

The pilot programme supply chain represents an early-stage commercial opportunity. Trial dispensaries are required to source cannabis from FOPH-approved Swiss producers — a deliberate policy choice to build domestic industry rather than rely on imports. Several Swiss cultivators and processing companies have established operations to serve the pilot supply chain, with an eye on the larger opportunity that national regulation would create.

For investors, Switzerland's evidence-based approach reduces the political risk typical of cannabis market entry. The trial data will provide unusually robust epidemiological evidence for investment thesis construction, and the country's political stability and legal clarity make it an attractive base for European holding structures.

CBD in Switzerland

Switzerland's CBD framework is among the most permissive in Europe. Products containing 1% THC or less — a threshold significantly higher than the EU's 0.3% Novel Foods ceiling — can be sold legally in Switzerland without prescription. Cannabis Sativa plants bred for low THC content are cultivated across Swiss cantons, and a thriving domestic CBD retail sector has developed serving both domestic consumers and cross-border visitors. Swiss CBD brands have established international export operations, though they face regulatory barriers in EU member states whose frameworks are more restrictive.

Penalties and Enforcement

Switzerland's enforcement environment reflects its pragmatic approach to drug policy. Possession of up to 10g carries a CHF 100 fixed fine administered on the spot — no court appearance, no record. Authorities have discretion to overlook very small quantities in some cantons. Supply and trafficking are prosecuted under the BetmG with penalties reflecting quantity and organisation: personal-scale supply may attract fines or short sentences, while commercial trafficking carries custodial terms of up to three years for basic offences, longer for aggravated cases involving organised crime or large quantities.

External reference: Federal Office of Public Health (FOPH) — Swiss drug policy